Thymalin: What It Is, Where to Get It Prescribed, and What It Costs

Thymalin is a polypeptide complex — a mixture of short peptides — extracted from the thymus gland of young cattle. That separates it from almost every other peptide on this site. BPC-157, thymosin alpha-1 and semaglutide are each one defined amino acid sequence a chemist can synthesise; thymalin is a standardised extract. The group that developed it describes two dipeptides — Lys-Glu (KE) and Glu-Trp (EW) — as the active components inside the mixture, and most of the later mechanism work has been done on those two fragments.

The thymus is the organ in which T-lymphocytes mature. It is large in childhood and shrinks steadily from puberty onward, and the loss of thymic output is one of the best-described contributors to the weakening of the immune system in older age. The rationale behind thymalin is to supply signalling peptides from thymic tissue to a body whose own thymus has largely stopped producing them.

Thymalin was developed in the Soviet Union by Vladimir Khavinson and Vyacheslav Morozov, working from 1973 onward at what became the St. Petersburg Institute of Bioregulation and Gerontology. It was the first of a family of tissue-specific peptide preparations the group went on to produce, including the pineal extract Epithalamin and its synthetic successor Epitalon. Thymalin has been used clinically in Russia for decades, including in hospital treatment of COVID-19, which is where the most recent human reports come from.

This provenance matters for reading the evidence. Almost all of the literature comes from one research group and its collaborators, much of it in Russian-language journals, and the study designs described are not the randomised, blinded trials Western regulators require. That does not make the work wrong. It means it should be read as what it is: a long clinical tradition from one country, with a mechanistic story only recently examined outside it.

Thymalin is not thymosin alpha-1. Both are "thymic peptides" sold for immune support, and that is roughly where the resemblance ends. Thymosin alpha-1 is a single 28-amino-acid synthetic sequence with a branded product approved in a number of countries outside the United States and a large international trial literature. Thymalin is a natural extract with a Russian literature. A physician choosing between them is choosing between two kinds of evidence, not two doses of the same thing. The comparison section below covers this.

It is not a hormone, not a steroid and not a vaccine. It is not an antibiotic or an antiviral and does not treat an infection directly; the research describes it acting on the immune cells that respond to infection, which is a different claim. And it is not a treatment for a diagnosed immunodeficiency, which is a specialist question with its own established therapies.

A 2020 paper in the Bulletin of Experimental Biology and Medicine exposed human hematopoietic stem cells — the bone-marrow cells that give rise to every blood cell — to thymalin in culture. It reported reduced expression of CD44 and CD117, markers of stem cells and of an intermediate stage of differentiation, by two to three times, and increased expression of CD28, a marker of mature T-lymphocytes, by nearly seven times. The authors read this as thymalin nudging progenitor cells along the path to mature T-cells. It is a cell-culture finding, and the paper says the molecular mechanism still requires study, but it is the clearest description of what "restoring T-cell function" is supposed to mean at the cellular level.

The group's 2023 paper in the International Journal of Molecular Sciences took the two active dipeptides, KE and EW, and asked what they might be doing inside a cell. Molecular modelling described each binding preferentially to a short DNA sequence, and bioinformatics linked their potential target genes to the AKT1 and AKT2 proteins involved in cytokine signalling. Tested on human peripheral blood mononuclear cells stimulated with bacterial lipopolysaccharide, thymalin and both dipeptides were reported to reduce synthesis of the inflammatory cytokines IL-1β, IL-6 and TNF-α by 1.4 to 6 times. The proposed model is that the extract's immune effect runs through its dipeptides regulating proteins in an inflammatory cascade.

A 2022 study in the same journal, run in Italy with the St. Petersburg group as co-authors, tested thymalin alongside four other Khavinson peptides on THP-1 cells, a human monocyte line that can be driven to become macrophages. All five reduced expression of TNF and IL-6 in differentiated cells stimulated with lipopolysaccharide, and reduced adhesion of those cells to activated endothelial cells, an early step of an inflammatory response. The authors' interpretation is that the peptides act as natural inducers of TNF tolerance, a documented mechanism by which monocytes attenuate their own inflammatory output. Again, cells in a dish.

The human data comes from Russian COVID-19 wards. A 2021 paper in Stem Cell Reviews and Reports reported that patients receiving thymalin alongside standard treatment showed a faster decline in IL-6, C-reactive protein and D-dimer than controls on standard treatment alone, along with changes in T-cell indicators. A 2022 paper in Advances in Gerontology, in middle-aged and elderly patients with severe COVID-19, described the thymalin group with higher lymphocyte and monocyte counts and lower fibrinogen, lactate dehydrogenase and D-dimer than standard care. The mechanistic reading is that the cell effects show up as movement in inflammation and coagulation markers in people. Whether they translate into outcomes is the next section's question.

The foundational human work is the long observational programme reported in Advances in Gerontology in 2002 and, in English, in Neuroendocrinology Letters in 2003. Researchers in St. Petersburg and Kiev followed 266 elderly and older persons over six to eight years, treating with thymalin, with the pineal extract Epithalamin, or with both, for the first two to three years, and compared them with controls. The papers report improvements across cardiovascular, endocrine, immune and nervous system indices, a 2.0 to 2.4-fold reduction in the incidence of acute respiratory disease, and a mortality rate over the observation period 2.0 to 2.1 times lower in the thymalin group than in controls, with larger differences reported for the combination.

Those are striking numbers and they need to be read carefully. The abstracts do not describe randomisation, blinding or placebo, and the work has not been replicated by an independent group. It is the largest and longest body of human experience with thymalin and the reason the compound is used for age-related immune decline; it is not a trial in the sense a regulator would use the word.

Two hospital studies, both described above. The 2021 paper framed the faster fall in IL-6, C-reactive protein and D-dimer as a reduced risk of clotting complications. The 2022 paper, in severe disease in middle-aged and elderly patients, reported lower in-hospital mortality in the thymalin group than in the standard-care group, and a more favourable profile of blood counts and clotting markers than with tocilizumab. Neither abstract describes randomisation or blinding, group sizes are not given, and the second paper's English and Russian abstracts report slightly different mortality figures, which is why no percentage is quoted here. This was pandemic-era work done under pressure in one country's health system: real clinical experience, and not an RCT.

The St. Petersburg group's papers state that thymalin has been used in the therapy of acute respiratory distress syndrome, chronic obstructive bronchitis and other immunopathology. Those statements reflect its clinical use in Russia rather than trials that can be examined here: reported by the developers, not established in published controlled studies.

Beyond the immune-cell studies above, thymalin appears in a scattering of animal work — a 2018 rat study of tumour and thymus tissue in the Bulletin of Experimental Biology and Medicine, and 2024 Ukrainian papers on experimental jaw-bone defects in rats. These are peripheral to why it is prescribed and are mentioned for completeness, not as support.

There are no randomised controlled trials of thymalin. The human evidence is a long-running Russian observational programme in older adults, reported in 2002 and 2003, and two Russian hospital studies in COVID-19 patients from 2021 and 2022, none of whose published abstracts describes randomisation, blinding or placebo control. Several of the underlying papers are available only in Russian. There is no Western trial of thymalin, and the mechanism work outside Russia consists of cell studies co-authored with the developing group.

That is a thinner and more regionally concentrated human record than thymosin alpha-1 has, and it is fair to say so. It is also a longer clinical tradition than most compounded peptides can claim. The honest framing is "used clinically in Russia for decades, with mechanistic support from cell studies, and without controlled trials," and any source describing it as proven is overstating it.

• It does not establish that thymalin reduces infections or extends life in people. Those are the outcomes the Russian programme reports, and they have not been tested in a controlled design.
• It does not establish an effect size or a timeline in any population, because no trial has measured one.
• It does not establish that the cell-culture effects on T-cell maturation or cytokine output occur at the doses used in people.
• It does not establish long-term safety under modern pharmacovigilance.
• It does not establish efficacy for any condition as an FDA-approved treatment. It is not approved for anything in the United States.

Nothing about thymalin is expected to be felt. It does not act on energy, mood or sleep in any direct way, and prescribers generally describe the first fortnight as uneventful. Injection-site reactions, if any, tend to show up here and settle.

If the T-cell effects described in cell work happen in people, this is the window in which prescribers describe looking for them, usually indirectly: fewer or shorter minor infections over a season, or movement in immune markers if a physician has chosen to measure them. One vial is sized to this window.

The Russian programme treated older adults in courses repeated annually over several years, and that is the pattern most prescribers reference: a course, then reassessment against whatever was being watched, rather than open-ended daily use. Whether to repeat is your physician's call and depends on why it was started.

No withdrawal, rebound or dependence has been described. The compound is intended to shift the state of a cell population rather than to substitute for something the body makes each day, so nothing is expected to happen when it stops. Whether any benefit persists is a question nobody has run the study to answer.

The directions are written in millilitres and in insulin-syringe units because that is what you can read off the barrel. 0.25 mL is 25 units on a U-100 syringe. You are not calculating anything — the number is printed on your medication, and it is the same draw every time.

Subcutaneous means into the fat layer, not the muscle. Abdomen and thigh are the usual sites, rotated so the same spot is not used repeatedly. Because the mechanisms described are systemic — circulating immune cells, not a local tissue — there is no reason to inject near anything in particular. Your directions will say.

Five doses a week rather than seven is a pattern shared by a number of peptides on this site, and it reflects prescribing convention rather than a pharmacokinetic finding. 20 doses at five a week is four weeks, which is why refills run on a 28-day cycle. One vial per fill, always — not a stockpile.

Refrigerated, and it ships that way in insulated packaging with ice packs. Keep it cold, out of light, and do not freeze it. Beyond-use dating runs from first puncture and is on the label.

These are the two immune peptides Pepti supplies, so this is the comparison that matters. Thymosin alpha-1 is a single 28-amino-acid sequence, first isolated from a thymic fraction in the United States in the 1970s and now made synthetically; a branded version is approved in a number of countries outside the US, and it has randomised human trials. Thymalin is a natural extract from calf thymus, developed in Leningrad in the same decade, with two identified active dipeptides, a long Russian clinical history and no randomised trials. Both are described around T-cell maturation and immune regulation. Thymosin alpha-1 is the choice when a physician wants the controlled-evidence file; thymalin is the choice when the interest is specifically in the Russian geroprotective programme and the whole-extract approach. They are not the same thing under two names, and neither is FDA approved.

These are the two halves of the Khavinson programme. Epithalon is the synthetic tetrapeptide derived from the pineal extract Epithalamin, which was studied alongside thymalin in the 266-person Russian cohort. Thymalin is aimed at the thymus and the immune system; Epithalon is described around the pineal gland, melatonin rhythms and telomerase. Physicians familiar with that literature sometimes discuss them together rather than as alternatives.

The FORTIFY blend is Pepti's multi-component immune preparation, built around thymosin alpha-1 rather than thymalin, with BPC-157, KPV and LL-37 alongside. Thymalin on its own is for a physician who has decided a thymic extract is specifically what they want; FORTIFY is for when the immune component is one piece of a broader picture. Which is appropriate is your physician's decision.